Armed an­ti­body play­er ADC lands a $105M mega-round to back pipeline con­struc­tion

Chris Mar­tin’s ADC Ther­a­peu­tics has roped in a $105 mil­lion mega-round to back his an­ti­body-drug con­ju­gate start­up ADC Ther­a­peu­tics, based in Lau­sanne, Switzer­land. Found­ing in­vestor Au­ven Ther­a­peu­tics came back in for the sec­ond fundrais­ing, along with the Wild Fam­i­ly Of­fice and phar­ma gi­ant As­traZeneca, which has been part­nered with the biotech.

The biotech has now raised $255 mil­lion for its work, with plans to launch an IPO when the tim­ing is right. And some of this new mon­ey is be­ing re­served to build out man­u­fac­tur­ing op­er­a­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER